NDA 021695 · Lupin
Antara (Micronized)
Fenofibrate · Oral · Peroxisome Proliferator Receptor alpha Agonist
Last checked: Nov 19, 2026Latest source record: Oct 1, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Nov 30, 2004
Approved uses
2
Original approval plus efficacy supplements
Registered trials
211
64 Phase 3, 15 recruiting
FAERS reports
35,836
24,506 serious, 2,824 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 1, 2025.
Antara is indicated as adjunctive therapy to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. Limitations of Use Markedly elevated levels of serum TG (e.g., > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been determined [see Warnings and Precautions ( 5.7 )] . Fenofibrate did not reduce coronary heart disease morbidity and mortality in two large, randomized controlled trials of patients with type 2 diabetes mellitus [ see Warnings and Precautions ( 5.1 ) and Clinical Studies ( 14.4 ) ]. Antara is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL) ( 1 ). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible ( 1 ). Limitations of Use: Markedly elevated levels of serum TG (e.g., > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been determined ( 1 ). Fenofibrate did not reduce coronary heart disease morbidity and mortality in two large, randomized controlled trials of patients with type 2 diabetes mellitus ( 1 ).
Mechanism: The active moiety of Antara is fenofibric acid. The pharmacological effects of fenofibric acid in both animals and humans have been studied through oral administration of fenofibrate. The lipid-modifying effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of PPAR alpha receptor. Through this mechanism, fenofibric acid increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 21, 2005 Supplement 1 · Efficacy Letter
- Nov 30, 2004 Original approval · Type 3 - New Dosage Form LabelReviewLetter
5 products under this application
- ANTARA (MICRONIZED) · FENOFIBRATE 90MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
- ANTARA (MICRONIZED) · FENOFIBRATE 130MG · CAPSULE, ORAL · Prescription · TE AB
- ANTARA (MICRONIZED) · FENOFIBRATE 43MG · CAPSULE, ORAL · Prescription · TE AB
- ANTARA (MICRONIZED) · FENOFIBRATE 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
- ANTARA (MICRONIZED) · FENOFIBRATE 87MG · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Fenofibrate" as an intervention, any sponsor and status, largest first.
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on StatinPivotal-lookingCompleted
Amarin Pharma Inc.Industry
NCT01492361 · 8,179 participants · Start Nov 2011 · Primary completion May 2018
Drug: AMR101; Placebo and 1 more · For: Cardiovascular Diseases
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 410 sites in all
- To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DMPivotal-lookingRecruiting
Korea University Anam HospitalAcademic, hospital or other
NCT06293417 · 3,958 participants (planned) · Start Mar 1, 2024 · Primary completion Feb 1, 2027
Drug: Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin; Dose escalation of moderate-intensity statin · For: T2DM (Type 2 Diabetes Mellitus); Dyslipidemias
Sites: Seoul, South Korea
- Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00542178 · 3,472 participants · Start Oct 2003 · Primary completion Dec 2009
Drug: Hypoglycemic Agents; Standard glycemia control and 5 more · For: Diabetic Retinopathy
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.Pivotal-lookingCompleted
Solvay PharmaceuticalsIndustry
NCT00703755 · 2,288 participants · Start Mar 2003 · Primary completion Jun 2004
Drug: Fenofibrate /Metformin; Fenofibrate /Metformin and 5 more · For: Patients With Metabolic Syndrome
Sites: Calgary, Canada; Chicoutimi, Canada; Halifax, Canada · 101 sites in all
- Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.Pivotal-lookingCompleted
AbbottIndustry
NCT00300430 · 1,911 participants · Start Sep 2006 · Primary completion Mar 2008
Drug: ABT-335 and rosuvastatin calcium; ABT-335 and atorvastatin calcium and 1 more · For: Dyslipidemia; Coronary Heart Disease; Mixed Dyslipidemia
Sites: North Chicago, Illinois
- Lowering Events in Non-proliferative Retinopathy in ScotlandPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT03439345 · 1,151 participants · Start Jul 23, 2018 · Primary completion Nov 17, 2023
Drug: Fenofibrate 145 mg; Placebo Oral Tablet · For: Diabetic Retinopathy
Sites: Aberdeen, United Kingdom; Airdrie, United Kingdom; Ayr, United Kingdom · 16 sites in all
- Comparison of the Combination of Fenofibrate and 20 mg Simvastatin Versus 40 mg Simvastatin MonotherapyPivotal-lookingCompleted
Solvay PharmaceuticalsIndustry
NCT00349375 · 1,040 participants · Start Nov 2005 · Primary completion Sep 2008
Drug: Fenofibrate/Simvastatin; Fenofibrate/Simvastatin and 1 more · For: Hyperlipidemia
Sites: Brno, Czechia; Hradisk, Czechia; Karlovy Vary, Czechia · 110 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue2,202
- diarrhoea2,135
- nausea2,066
- drug ineffective1,826
- headache1,583
- dyspnoea1,561
- off label use1,420
- dizziness1,405
- pain1,399
- fall1,376
- asthenia1,331
- acute kidney injury1,288
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 264 |
| 2005 | 257 |
| 2006 | 404 |
| 2007 | 311 |
| 2008 | 482 |
| 2009 | 553 |
| 2010 | 670 |
| 2011 | 971 |
| 2012 | 1,096 |
| 2013 | 1,084 |
| 2014 | 1,374 |
| 2015 | 2,216 |
| 2016 | 2,581 |
| 2017 | 2,513 |
| 2018 | 2,797 |
| 2019 | 2,729 |
| 2020 | 2,502 |
| 2021 | 2,269 |
| 2022 | 2,233 |
| 2023 | 2,161 |
| 2024 | 2,068 |
| 2025 | 2,335 |
| 2026 | 1,966 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Fenofibrate on Progression of Diabetic Retinopathy.
Preiss D, Logue J, Sammons E, et al. · NEJM Evid 2024 · Randomized Controlled Trial
- Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial.
Liu Y, Guo G, Zheng L, et al. · Am J Gastroenterol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- G-estimation of structural nested mean models for interval-censored data using pseudo-observations.
Tanaka S, Brookhart MA, Fine J · Stat Med 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effects of combination lipid therapy in type 2 diabetes mellitus.
Ginsberg HN, Elam MB, Lovato LC, et al. · N Engl J Med 2010 · Multicenter Study, Randomized Controlled Trial
- Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.
Lawitz EJ, Bhandari BR, Ruane PJ, et al. · Clin Gastroenterol Hepatol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Fenofibrate for diabetic retinopathy.
Kataoka SY, Lois N, Kawano S, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Lupin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.